3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
36
Neoplasms
8
HER2-positive Breast Cancer
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Salivary Gland Neoplasms
2
Pathologic Complete Response
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
Liver Neoplasms
1
Hemangiosarcoma
1
Heart Failure
1
Interventions
Bevacizumab
76
Fluorouracil
56
Cetuximab
47
Leucovorin
44
Oxaliplatin
43
pembrolizumab
35
Irinotecan
34
Folfox protocol
24
Capecitabine
24
HMPL-013
22
Specimen Handling
18
trifluridine tipiracil drug combination
16
Nivolumab
15
Blood Specimen Collection
15
Panitumumab
14
regorafenib
13
Magnetic Resonance Spectroscopy
13
Trifluridine
12
Standard of Care
12
Gemcitabine
12
Biopsy
12
Cisplatin
11
sintilimab
10
Interviews as Topic
10
IFL protocol
10
Drug Therapy
10
Carboplatin
9
tislelizumab
8
Trastuzumab
8
Cyclophosphamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colorectal Neoplasms
×
pertuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled